Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
SERA Sera Prognostics
1.530+0.070+4.79%
Close
01/27 16:00 ET
1.5300.0000.00%
Post Mkt Price 01/27 16:00 ET
High
1.533
Open
1.533
Turnover
1.95K
Low
1.530
Pre Close
1.460
Volume
1.27K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Akumin (NASDAQ:AKU) & Sera Prognostics (NASDAQ:SERA) Critical Survey
Akumin (NASDAQ:AKU – Get Rating) and Sera Prognostics (NASDAQ:SERA – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on t
Sera Prognostics's Return On Capital Employed Overview
According to Benzinga Pro data, during Q3, Sera Prognostics (NASDAQ:SERA) posted sales of $87 thousand. Earnings were up 7.01%, but Sera Prognostics still reported an overall loss of $10.71 million. S
Castle Biosciences (NASDAQ:CSTL) Vs. Sera Prognostics (NASDAQ:SERA) Head to Head Comparison
Castle Biosciences (NASDAQ:CSTL – Get Rating) and Sera Prognostics (NASDAQ:SERA – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two busin
Castle Biosciences (NASDAQ:CSTL) Vs. Sera Prognostics (NASDAQ:SERA) Critical Analysis
Sera Prognostics (NASDAQ:SERA – Get Rating) and Castle Biosciences (NASDAQ:CSTL – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two compa
Sera Prognostics Is Maintained at Neutral by Citigroup
Sera Prognostics Is Maintained at Neutral by Citigroup
Sera Prognostics, Inc. (SERA) Reports Q3 Loss, Tops Revenue Estimates
Sera Prognostics Reports Q3 EPS (35c), Consensus (56c)
Sera Prognostics GAAP EPS of -$0.35
Sera Prognostics Q3 EPS $(0.35) Beats $(0.56) Estimate, Sales $87.00K Miss $100.00K Estimate
Sera Prognostics (NASDAQ:SERA) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.56) by 37.5 percent. This is a 10.26 percent increase over losses of $(0.
Press Release: SERA PROGNOSTICS REPORTS THIRD -2-
of laboratory-developed tests; the intellectual property rights protecting our tests and market position; and other factors discussed under the heading "Risk Factors" contained in our Quarterly Report
Company Overview
More
Sera Prognostics, Inc. engages in the provision of personalized diagnostics to predict and manage pregnancy complications. It focuses on developing blood tests to predict the risks of preterm birth, preeclampsia and other pregnancy complications. The company was founded by Steven W. Graves, Dennis Farrar and M. Sean Esplin in 2008 and is headquartered in Salt Lake City, UT.
CEO： Dr. Gregory C. Critchfield,M.D.
Market： NASDAQ
Listing Date： 07/15/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet